• Passage Bio shareholders approved merger-related share issuance to Remix Therapeutics securityholders at a November 5, 2026, special meeting.
• Stockholders authorized a reverse stock split ranging from 1-for-2 to 1-for-10, with the final ratio subject to mutual agreement.
• The restated charter won approval, including a name change to Remix Therapeutics effective at the second merger’s effective time.
• All nonbinding charter proposals passed, covering the name change, voting requirements and other governance provisions.
• Shareholders adopted the 2026 Equity Incentive Plan and Employee Stock Purchase Plan, effective upon completion of the first merger.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Passage Bio Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001140361-26-042222), on November 06, 2026, and is solely responsible for the information contained therein.